Braskem S.A. (BAK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2024, filed Mar 31, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BAK SEC filings page.
Braskem S.A. (BAK) reported $12.5B in revenue for fiscal year 2024, down 13.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Braskem S.A.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Braskem S.A. has an operating margin of -1.4%, meaning the company loses $1 on every $100 of revenue. This results in a profitability score of 26/100. This is up from -4.0% the prior year.
Braskem S.A.'s revenue declined 13.9% year-over-year, from $14.5B to $12.5B. This contraction results in a growth score of 5/100.
Braskem S.A.'s current ratio of 1.31 indicates adequate short-term liquidity, earning a score of 35/100. The company can meet its near-term obligations, though with limited headroom.
While Braskem S.A. generated $393.8M in operating cash flow, capex of $608.2M consumed most of it, leaving -$214.4M in free cash flow. This results in a low score of 20/100, reflecting heavy capital investment rather than weak cash generation.
Braskem S.A. scores 0.65, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $2.3B against total assets of $16.4B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Braskem S.A. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Braskem S.A. reported a net loss of $1.8B while generating $393.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Braskem S.A. reported an operating loss of $174.5M against $1.1B in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Braskem S.A. generated $12.5B in revenue in fiscal year 2024. This represents a decrease of 13.9% from the prior year.
Braskem S.A.'s EBITDA was $626.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.8% from the prior year.
Braskem S.A. reported a net loss of $1.8B in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Braskem S.A. recorded an outflow of $214.4M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Braskem S.A. held $2.4B in cash against $6.3B in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Braskem S.A.'s gross margin was 7.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 3.5 percentage points from the prior year.
Braskem S.A.'s operating margin was -1.4% in fiscal year 2024, reflecting core business profitability. This is up 2.6 percentage points from the prior year.
Braskem S.A.'s net profit margin was -14.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 8.1 percentage points from the prior year.
Not reported for fiscal year 2024.
Capital Allocation
Braskem S.A. invested $74.9M in research and development in fiscal year 2024. This represents a decrease of 5.1% from the prior year.
Braskem S.A. invested $608.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 34.9% from the prior year.
Not reported for fiscal year 2024.
BAK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5B-13.9% | $14.5B-20.3% | $18.3B-3.6% | $18.9B+68.1% | $11.3B-13.4% | $13.0B-12.9% | $14.9B+0.5% | $14.9B+1.5% | $14.7B+23.7% | $11.8B |
| Cost of Revenue | $11.5B-17.0% | $13.9B-13.6% | $16.1B+22.1% | $13.2B+44.8% | $9.1B-20.2% | $11.4B-4.9% | $12.0B+9.9% | $10.9B+1.6% | $10.8B+16.0% | $9.3B |
| Gross Profit | $969.8M+55.8% | $622.6M-71.0% | $2.1B-62.6% | $5.8B+166.4% | $2.2B+34.6% | $1.6B-45.5% | $2.9B-25.5% | $4.0B+1.4% | $3.9B+51.5% | $2.6B |
| R&D Expenses | $74.9M-5.1% | $78.9M+11.6% | $70.8M+32.8% | $53.3M+10.4% | $48.3M-21.7% | $61.6M+9.1% | $56.5M+11.8% | $50.6M+1.5% | $49.8M+16.2% | $42.8M |
| Operating Income | -$174.5Mn/m | -$575.4M-171.2% | $808.2M-82.7% | $4.7Bn/m | -$13.8M-136.2% | $38.2M-98.2% | $2.1B-23.2% | $2.8B+52.0% | $1.8B+5.1% | $1.7B |
| EBITDA | $626.0M+25.8% | $497.5M-70.8% | $1.7B-68.6% | $5.4B+608.1% | $765.6M-18.7% | $942.0M-67.6% | $2.9B-20.7% | $3.7B+38.1% | $2.7B+16.6% | $2.3B |
| Interest Expense | $1.1B-3.8% | $1.2B+20.2% | $958.4M+9.0% | $879.5M-7.0% | $946.1M-2.1% | $966.1M+24.6% | $775.1M+15.7% | $670.1M-10.9% | $752.3M+42.2% | $529.0M |
| Income Tax | -$918.7Mn/m | -$268.3M-263.4% | $164.2M-77.1% | $717.3Mn/m | -$513.8Mn/m | -$488.3M-357.3% | $189.8M-53.7% | $409.9M+116.5% | $189.4M-54.8% | $419.4M |
| Net Income | -$1.8Bn/m | -$943.7Mn/m | -$63.6M-102.5% | $2.5Bn/m | -$1.3Bn/m | -$632.2M-186.8% | $728.7M-37.6% | $1.2Bn/m | -$126.5M-116.7% | $758.1M |
| EPS (Basic) | N/A | N/A | N/A | $3.15n/m | -$1.62n/m | -$0.79 | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | $3.15n/m | -$1.62n/m | -$0.79 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: SG&A Expenses, Diluted Shares (Avg).
BAK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.4B-13.1% | $18.9B+13.5% | $16.7B+0.3% | $16.6B+0.2% | $16.6B-2.2% | $17.0B+11.9% | $15.2B-4.8% | $15.9B-0.1% | $15.9B | N/A |
| Current Assets | $6.0B-22.4% | $7.7B+18.4% | $6.5B-7.5% | $7.0B+7.1% | $6.6B+13.1% | $5.8B+7.4% | $5.4B+3.1% | $5.3B+7.6% | $4.9B | N/A |
| Cash & Equivalents | $2.4B-17.1% | $2.9B+24.0% | $2.4B+51.4% | $1.6B-41.7% | $2.7B+57.7% | $1.7B+18.4% | $1.4B+25.4% | $1.1B-44.7% | $2.1B+15.8% | $1.8B |
| Inventory | $2.2B-14.3% | $2.6B-2.7% | $2.7B-9.4% | $2.9B+81.5% | $1.6B-14.9% | $1.9B-13.2% | $2.2B+9.1% | $2.0B+24.5% | $1.6B | N/A |
| Goodwill | $547.7M-14.5% | $640.5M+12.0% | $571.7M+10.7% | $516.2M-5.2% | $544.7M-20.7% | $687.3M-2.7% | $706.4M-14.2% | $823.5M-1.8% | $838.4M | N/A |
| Total Liabilities | $17.2B-4.9% | $18.1B+18.4% | $15.3B+0.5% | $15.2B-10.6% | $17.0B+8.0% | $15.7B+16.8% | $13.5B-3.9% | $14.0B-7.1% | $15.1B | N/A |
| Current Liabilities | $4.6B-9.4% | $5.0B+10.3% | $4.6B+1.2% | $4.5B-17.3% | $5.5B+35.5% | $4.0B-31.2% | $5.9B+4.7% | $5.6B-20.5% | $7.1B | N/A |
| Non-Current Liabilities | $12.5B-4.8% | $13.2B+20.7% | $10.9B-0.4% | $11.0B-7.4% | $11.9B-0.7% | $11.9B+52.4% | $7.8B-9.6% | $8.7B+4.1% | $8.3B | N/A |
| Long-Term Debt | $6.3B-3.7% | $6.5B+37.1% | $4.8B+17.3% | $4.1B-43.4% | $7.2B+46.1% | $4.9B-21.0% | $6.2B-7.0% | $6.7B+5.0% | $6.4B | N/A |
| Total Equity | -$773.3M-194.0% | $822.7M-40.6% | $1.4B-1.8% | $1.4Bn/m | -$424.1M-134.9% | $1.2B-27.8% | $1.7B-11.5% | $1.9B+126.0% | $841.8M+252.5% | $238.8M |
| Retained Earnings | -$2.3Bn/m | -$564.3M | N/A | N/A | -$872.2M | N/A | -$66.1Mn/m | -$65.7M | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments.
BAK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $393.8Mn/m | -$468.3M-127.6% | $1.7B-36.1% | $2.7B+118.9% | $1.2B+115.0% | $563.6M-76.4% | $2.4B+220.7% | $743.2M-45.8% | $1.4B-23.5% | $1.8B |
| Depreciation & Amortization | $800.5M-25.4% | $1.1B+19.8% | $895.4M+19.5% | $749.4M-3.9% | $779.5M-13.8% | $903.8M+17.3% | $770.7M-12.8% | $884.3M+7.2% | $824.8M+53.6% | $536.9M |
| Capital Expenditures | $608.2M-34.9% | $933.6M+1.8% | $917.1M+49.5% | $613.6M+15.5% | $531.4M-20.4% | $667.5M-4.3% | $697.4M+1.6% | $686.3M-13.7% | $795.1M-5.7% | $843.1M |
| Free Cash Flow | -$214.4Mn/m | -$1.4B-280.6% | $776.4M-61.9% | $2.0B+199.7% | $680.3Mn/m | -$103.8M-106.2% | $1.7B+2864.4% | $56.9M-90.1% | $575.2M-39.3% | $948.1M |
| Investing Cash Flow | -$563.6Mn/m | -$932.6Mn/m | -$935.9Mn/m | -$606.5Mn/m | -$524.1Mn/m | -$663.5Mn/m | -$641.3Mn/m | -$726.5Mn/m | -$784.6Mn/m | -$842.1M |
| Financing Cash Flow | $75.8M-95.9% | $1.8B+4196.2% | $42.6Mn/m | -$3.0B-827.3% | $418.5M+2.7% | $407.3Mn/m | -$1.2Bn/m | -$902.3Mn/m | -$847.6Mn/m | -$24.6M |
| Dividends Paid | $970K-32.7% | $1.4M-99.4% | $255.4M-76.2% | $1.1B+234479.7% | $458K-99.7% | $166.4M-56.9% | $386.5M+28.2% | $301.6M-50.9% | $614.2M+404.4% | $121.8M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $234K |
Not reported in any period shown, so not listed: Stock-Based Compensation.
BAK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 7.8%+3.5pp | 4.3%-7.5pp | 11.8%-18.6pp | 30.3%+11.2pp | 19.1%+6.8pp | 12.3%-7.4pp | 19.7%-6.9pp | 26.6%0.0pp | 26.6%+4.9pp | 21.7% |
| Operating Margin | -1.4%+2.6pp | -4.0%-8.4pp | 4.4%-20.2pp | 24.7%+24.8pp | -0.1%-0.4pp | 0.3%-14.0pp | 14.3%-4.4pp | 18.7%+6.2pp | 12.5%-2.2pp | 14.7% |
| Net Margin | -14.6%-8.1pp | -6.5%-6.1pp | -0.4%-13.6pp | 13.2%+24.7pp | -11.4%-6.6pp | -4.9%-9.7pp | 4.9%-3.0pp | 7.8%+8.7pp | -0.9%-7.3pp | 6.4% |
| Return on Equity | N/A | -114.7%-110.1pp | -4.6%-182.4pp | 177.8% | N/A | -52.0%-95.3pp | 43.3%-18.1pp | 61.4%+76.4pp | -15.0%-332.5pp | 317.5% |
| Return on Assets | -11.1%-6.2pp | -5.0%-4.6pp | -0.4%-15.5pp | 15.1%+22.9pp | -7.8%-4.0pp | -3.7%-8.5pp | 4.8%-2.5pp | 7.3%+8.1pp | -0.8% | N/A |
| Current Ratio | 1.31-0.2x | 1.53+0.1x | 1.42-0.1x | 1.56+0.4x | 1.20-0.2x | 1.44+0.5x | 0.920.0x | 0.94+0.2x | 0.69 | N/A |
| Debt-to-Equity | N/A | 7.95+4.5x | 3.44+0.6x | 2.88 | N/A | 4.05+0.3x | 3.70+0.2x | 3.52-4.1x | 7.57 | N/A |
| Liabilities-to-Equity | N/A | 21.98+11.0x | 11.03+0.3x | 10.77 | N/A | 12.95+4.9x | 8.00+0.6x | 7.37-10.6x | 17.92 | N/A |
| Asset Turnover | 0.760.0x | 0.77-0.3x | 1.100.0x | 1.14+0.5x | 0.68-0.1x | 0.77-0.2x | 0.99+0.1x | 0.930.0x | 0.92 | N/A |
| FCF Margin | -1.7%+7.9pp | -9.6%-13.9pp | 4.3%-6.5pp | 10.8%+4.7pp | 6.0%+6.8pp | -0.8%-12.1pp | 11.3%+10.9pp | 0.4%-3.6pp | 3.9%-4.1pp | 8.0% |
Note: Shareholder equity is negative (-$773.3M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Braskem S.A. BAK | FY2024 | $12.5B | -$1.8B | -14.6% | $474.2M | 20/100 |
| Huntsman Corporation HUN | FY2025 | $5.7B | -$284.0M | -5.0% | $1.6B | 24/100 |
| REX American Resources Corp. REX | FY2025 | $650.5M | $83.0M | 12.8% | $1.3B | 60/100 |
| TRONOX LIMITED CL A TROX | FY2025 | $2.9B | -$470.0M | -16.2% | $594.1M | 30/100 |
| WESTLAKE CHEMICAL PARTNERS LP WLKP | FY2025 | $1.2B | $48.7M | 4.2% | $745.1M | 73/100 |
| ASP Isotopes Inc. ASPI | FY2025 | $23.8M | -$159.8M | N/A | $311.2M | 52/100 |
Where Braskem S.A. Ranks
Frequently Asked Questions
What is Braskem S.A.'s annual revenue?
Braskem S.A. (BAK) reported $12.5B in total revenue for fiscal year 2024. This represents a -13.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Braskem S.A.'s revenue growing?
Braskem S.A. (BAK) revenue declined by 13.9% year-over-year, from $14.5B to $12.5B in fiscal year 2024.
Is Braskem S.A. profitable?
No, Braskem S.A. (BAK) reported a net loss of $1.8B in fiscal year 2024, with a net profit margin of -14.6%.
What is Braskem S.A.'s EBITDA?
Braskem S.A. (BAK) had EBITDA of $626.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Braskem S.A. have?
As of fiscal year 2024, Braskem S.A. (BAK) had $2.4B in cash and equivalents against $6.3B in long-term debt.
What is Braskem S.A.'s gross margin?
Braskem S.A. (BAK) had a gross margin of 7.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Braskem S.A.'s operating margin?
Braskem S.A. (BAK) had an operating margin of -1.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Braskem S.A.'s net profit margin?
Braskem S.A. (BAK) had a net profit margin of -14.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Braskem S.A.'s free cash flow?
Braskem S.A. (BAK) recorded an outflow of $214.4M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Braskem S.A.'s operating cash flow?
Braskem S.A. (BAK) generated $393.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Braskem S.A.'s total assets?
Braskem S.A. (BAK) had $16.4B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Braskem S.A.'s capital expenditures?
Braskem S.A. (BAK) invested $608.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Braskem S.A. spend on research and development?
Braskem S.A. (BAK) invested $74.9M in research and development during fiscal year 2024.
What is Braskem S.A.'s current ratio?
Braskem S.A. (BAK) had a current ratio of 1.31 as of fiscal year 2024, which is considered adequate.
What is Braskem S.A.'s return on assets (ROA)?
Braskem S.A. (BAK) had a return on assets of -11.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Braskem S.A.'s P/E ratio?
Braskem S.A. (BAK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $474.2M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Braskem S.A.'s price-to-sales ratio?
Braskem S.A. (BAK) trades at 0.0x sales, its market capitalization divided by $12.5B revenue, FY2024. The market capitalization is $474.2M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Braskem S.A.'s debt-to-equity ratio negative or not reported?
Braskem S.A. (BAK) has negative shareholder equity of -$773.3M as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Braskem S.A.'s Altman Z-Score?
Braskem S.A. (BAK) has an Altman Z-Score of 0.65, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Braskem S.A.'s Piotroski F-Score?
Braskem S.A. (BAK) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Braskem S.A.'s earnings high quality?
Braskem S.A. (BAK) reported a net loss of $1.8B while generating $393.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Braskem S.A. cover its interest payments?
Braskem S.A. (BAK) reported an operating loss of $174.5M against $1.1B in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Braskem S.A.?
Braskem S.A. (BAK) scores 20 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.